arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

EXAGEN INC.

XGN
$6.87 ▲ +0.26 (+3.93%) at close
Healthcare ·Services-Medical Laboratories ·USServices-Medical Laboratories
34 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

EXAGEN INC. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $163.9M
Dividend Yield
Revenue Growth 11.7%
Op. Margin -19.7%
ROIC -7.2%
FCF / Share $-0.45
Trailing P/E
Price / Book 11.5x
FCF Yield
Debt / Equity 1.58
info Valuation on last close. End-of-day price, Aug 7, 2026.

34-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$17.31M
↑ +11.7%
Net Income Profit after all expenses
$-3.97M
↓ -5.7%
Operating Margin Operating profit as % of sales
-19.7%
↑ +34.1% 10th
FCF / Share Free cash flow per share
$-0.45
↑ +23.2%
Long-Term Debt Long-term obligations
$22.87M
— -0.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)
  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
9
Returns
7
Financial Health
29
Cash Quality
49

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 34 quarters